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The rejection of rat renal allografts is provoked principally by antigens of the major 
histocompatibility complex (MHC), 1 H-1 (1-3). While incompatibility at H-1 usually 
leads to acute rejection of the allograft, incompatibilities for minor histocompatibility 
antigens do not. (There are some exceptions to both generalizations (see reference 4, 
for a compilation of results obtained in several different strain combinations). 
Injection of antibodies directed at MHC antigens of the donor into the recipient 
can cause prolonged survival of the transplanted allograft (passive enhancement) (5). 
Furthermore it  has been  shown  that  alloantibodies not  absorbable  by donor-type 
platelets or erythrocytes (RBC)  can enhance rat  kidney allografts (6)  as had been 
demonstrated previously for heterotopic rat heart grafts (7). These antibodies appear 
to be directed at the rat equivalent of the mouse Ia antigens, and it has been suggested 
that only antibodies of this specifitzity can mediate enhancement and that they do so 
by blocking lymphocyte-aetivating determinants present in the graft (6, 8). 
Two subregions of the rat MHC have been defined by recombination (9,  10). The 
H-1A  region resembles an isolated mouse H-2K or H-2D region or possibly both; the 
H-IB region is the probable homologue of the mouse H-2! region. By making use of 
the H-1 "cl recombinant haplotype (9), it has been possible to study the influence of 
subregions of the MHC on kidney graft rejection and enhancement. In the strain 
combinations employed, only kidneys histoincompatible at both the H-IA and H-IB 
regions  were  rejected.  In  addition,  alloantibodies  directed  at  either  of  the  two 
subregions alone enhanced kidney allografts presenting full H-l"  haplotype (H-1A a 
+  H-1B  a) differences. 
Materials and Methods 
Animals.  PVG (H-I  c) and DA (H-I  a) rats were maintained in the SPF colony of the MRC 
Cellular Immunology Unit, Oxford, The MHC recombinant 1R has been described elsewhere 
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(9). This recombinant defines two subregions of the rat MHC named H-IA and H-IB (11). The 
recombinant haplotype H-I  "cl  (which inherits its H-1A region from H-I"  (DA)  and its H-IB 
region from H-I c [PVG]) and the H-I a (DA) haplotype are being back-crossed on to the PVG 
background in the establishment of a series of congenic strains at the ARC Institute of Animal 
Physiology, Babraham, Cambridge.  Surplus animals from  the  PVG-H-I  a  and PVG-H-I  acl 
congenic programs were used in these experiments: H-I'~/H-1  c heterozygotes and their H-f/H- 
1" littermates came from the N6 and N7 generations; H-lUll~H-1 * heterozygotes from the N6, 
NT, and N8 generations. H-I°~t/H-I ~I homozygotes came from either the original 1R  (old) 
homozygous line N3F>2 or from the N6F1  generation. (AO ×  PVG)FI rats (H-lW/H-I ~) were 
also bred at Babraham. 
Antistra.  Antisera were  obtained from  animals immunized at  three-weekly intervals by 
subcutaneous and intraperitoneal injection of pooled spleen and lymph node cells, and bled 
7-8 days later. Some animals had been primed with a graft of belly skin. Serum donors: (AO 
X  PVG)F1 anti-PVG-H-1  ~ (anti-H-1  a) was from six c~ rats, (AO X  PVG)F1 anti-PVG-H-1  a~l 
(1R) (anti-H-lA a) from two ~ rats and (1 R  ×  PVG)F1 anti-PVG-H-1  a (anti-H-l/~) from six 
rats. 
These antisera had titers of 1/3,000,  1/3,000,  and 1/1,000, respectively. These titers, defined 
here as the dilution at which the antiserum kills half the number of cells killed at the cytotoxic 
plateau, were measured in a lymphocytotoxicity test in which serial dilutions of antiserum were 
incubated for 1 h at 37°(2 in a final vol of 75 #l containing 50,000 target lymph node cells and 
1:5  once-thawed guinea pig  serum.  (2ytotoxicity was  measured  by  trypan blue exclusion. 
Antisera were stored at -20°C. (AO X  PVG)FI and (1R X  PVG)F1 normal sera were used as 
controls. 
Renal  Transplantation.  Left  orthotopic  renal  transplantation was  performed  as  described 
elsewhere (12). Technical success of the vascular and ureteric anastomoses was checked on the 
3rd d  after transplantation. Delayed nephrectomy was performed on day 5, before and after 
which all animals produced urine. Blood urea nitrogen (BUN) levels were determined every 
day up to day 14, every other day up to day 20, and weekly thereafter. The normal BUN was 
30  ±  9 mg %. At the time of transplantation all animals received  1 ml i.v. of one of three 
antisera or normal rat serum (NRS), or a smaller dose of antiserum diluted to 1 ml with NRS. 
This treatment was repeated 24 h later. 
Cell Preparation.  Thoracic duct lymphoeytes (TDL) were prepared essentially as described 
by Ford and Hunt (13). Suspensions of spleen lymphocytes were prepared by pressing the tissue 
through a wire screen followed by treatment with a Tris-buffered ammonium chloride solution 
(14) to lyse RB(2. Lymphoeytes were washed in Dulbecco's A and B solution containing 10% 
fetal calf serum and 0.01 M NaNa (DAB/F(2S/NaNa). 
RB(2 were obtained from rats which had received  1,000 fads 137(2s whole body irradiation 
(120 fads/rain) 4-6 days earlier. They were collected into anti-coagulant, washed in phosphate- 
buffered saline (PBS), and centrifuged 15 rain at 460 g through a Ficoll-Isop6aque solution (sp 
gr =  1.094). The resultant RB(2 suspensions had fewer than 1 leukocyte/10  RB(2. 
Analysis  of Antisera 
BINDING ASSAY.  A radioimmunoassay  described in detail elsewhere (15) was used. 106 target 
cells (DA RB(2, spleen lymphocytes or TDL, prepared as described above) were incubated with 
20 #1 of antiserum (diluted with DAB/F(2S/NaNa) for 1 h at 4°C. The cells were then washed 
and incubated with 20 #1 of immunoabsorbent purified x2SI-labeled rabbit-anti-ratFct~a,~d2b 
(2.1 #g/ml)  (for TDL targets), or rabbit-anti-rat F(ab')2 (2.8 #g/mi)  (for RB(2 targets). The 
preparation of these reagents is described elsewhere  (15). Cells were washed before gamma 
counting. 
For analysis on the fluorescence-activated cell sorter (FACS) 5 ×  106 targets, 50 #1 of diluted 
antiserum, and 50 #1 of fiuoresceinated second-stage antibody (the same reagents as used in the 
binding assays) were used in a similar protocol. 
ABSORVrXON ASSAYS.  For the serum absorption studies, 200  or 300-#1 samples of diluted 
antiserum were absorbed once with fourfold increasing numbers of cells for 2 h at 4°C with 
frequent agitation. After absorption and centrifugation the supernates were tested for residual 
binding  activity to DA RB(2 or TDL in the binding  assay described above. Control absorptions 
with PVG cells were always included. 246  MAJOR  HISTOCOMPATIBILITY  COMPLEX  REGIONS 
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Fie.  1.  Clinical course of five PVG recipients of H-P/H-f  kidneys (A) and two PVG recipients 
of H-f/H-I ~ kidneys (C)) presented as the mean -4- SD of the BUN level. 
TABLE  I 
Survival of H-laCl/H-1 aca and H-I"*I/H-1 ~ Renal Allografls in PVG Recipients 
(an H- I A ~ Incompatibility) 
Gene dose of H-  Survivors* (>35  Recipients  Genetic  status of donors  1A  a incompati-  days) 
bility 
3  H-laC~/H-lC  (N6-NS)  1  3/3 
5  H- laC~/H-l~*~ (N3F>2)  2  4/5:~ 
2  H- l'~C~/H-  i  "c~ (N6F  i)  2  2/2 
All rats received 2 ml NRS administered as described in Materials and Methods. 
* Only in the single case of rejection (see*) was any significant rise in BUN level seen. 
One  rat  died on  day  10  with  no evidence of technical failure,  i.e.,  a  presumed 
rejection. 
Results 
Rejection.  Rejection  through  the  full  H-1 ~  haplotype:  since  the  H-I a  --*  H-1 c 
combination  had  not  previously been used in experimental kidney transplantation, 
an initial group of transplants was performed for comparison with published data on 
other strains.  Five PVG rats received (PVG  X  DA)F1 kidneys and 2 ml NRS. They 
rejected the grafts vigorously and died by day 11 with markedly elevated BUN levels 
(data not shown). A second group of five PVGs received partially congenic H-la/H - 
1  c heterozygous kidneys (for genetic status of congenic animals used see Materials and 
Methods)  and  2  ml NRS.  These rats also rejected their grafts vigorously, dying by 
day 10 (Fig.  1). Finally two other PVG rats received H-f/H-f  homozygous kidneys 
(from littermates of the H-la/H:I  c donors used above) and 2 ml NRS: they survived 
long term (Fig.  1). These results demonstrated,  as expected, that an H-P  difference 
alone was sufficient for rejection irrespective of allotypic differences at loci not linked 
to the MHC. 
REJECTION  THROUGH H-1A ~.  I0 PVG rats received kidneys presenting H-IA a as a 
homozygous or a  heterozygous incompatibility. Only one recipient rejected its graft 
(Table  I), while  no  other  rat  showed  a  significant  rise  in  BUN  level  in  the  post- 
operative period. 
REJECTION THRCUGH H-IB ~.  Four H-I~*a/H-I ~ heterozygotes received H-I~/H-I  c Fic. 2. 
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Clinical course of four H-/"Cl/H-lC recipients of H-la/H - U  kidneys. 
TABLE II 
The Passive Enhancement of H-la/H-f  Renal Allografls  in PVG Recipients 
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No. surviv- 
Graft type  Treatment  Recipients  ing* longer  No. surviving >35 days 
than controls 
(PVG X DA)F12 ml Anti-H-l"  5  4  4 (t d.l 1) 
H-I~/H-ff  "  5  5  2 (t d.12, af d.14, t  d.18) 
H-la/H-1  ~  2 ml Anti-H-IB  a  6  5  5 (f d.10) 
H-ta/H-1  c  0.2 ml Anti-H-lB'* +  1.8 ml  5  5  3 (1" d.12, t  d.18) 
NRS 
H-I"/H-U  2 ml Anti-H-1A  a  5  5  3 (~" d.12, 1" d.16) 
* Control rejections (described in previous section) (PVG ×  DA)F1 ~  PVG 5/5 by day 11. H-I"/H-I~---~ 
PVG 5/5 by day 10. 
heterozygous  kidneys,  providing  an  H-IB"  incompatibility in  a  single  gene  dose. 
Although  there  was  considerable  elevation  of the  early  BUN  levels,  all  four  rats 
survived (Fig. 2). It appeared, therefore, that incompatibility at both H-1A and H-1B 
was necessary for acute rejection. 
Passive  Enhancement.  Table  II summarizes  the results of passive enhancement  in 
the  H-la/H-1 c  -.-*  H-1 ~ combination.  Preliminary  studies  had  indicated  that  this 
combination was difficult to enhance and that 2 ml of anti-H-1  a serum was approxi- 
mately the optimum dose. As shown, serum directed against the whole H-I a haplotype, 
or against the H-IA ~ or H-1B  ~ subregions in isolation, were enhancing. 
These enhancement studies demonstrated that a renal allograft presenting a  full H- 
I a haplotype difference to the recipient can be enhanced by antisera directed at two 
distinct  subregions  of that  haplotype.  These  antisera,  anti-H-1A a  and  anti-H-1B  a, 
have been shown  to detect K/D-like and  Ia-like antigens of the rat, respectively (9, 
16). Since antibodies against rat Ia-like antigens are thought to be active components 
of enhancing alloantisera (6, 8) the results with the anti-H-1A ~ serum were a  surprise. 
An analysis of this antiserum  was  undertaken  to discover whether  it contained any 
antibodies  against  Ia-like antigens.  This  was  possible  if the  cross-over which  had 
produced  the  H-I ~cl  haplotype  had  occurred  within  (rather  than  outside)  the  rat 
equivalent of the mouse I  region, so that the recombinant inherited an I  region locus 248  MAJOR  HISTOCOMPATIBILITY  COMPLEX  REGIONS 
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Fic.  3.  Exhaustive absorption of the anti-H-I  a serum with DA RBC leaves a  plateau of binding 
to DA TDL. ", O: binding to DA TDL after absorption with DA RBC and spleen cells, respectively. 
A: binding to DA RBC after absorption with DA RBC. A, F-I: binding to DA RBC and DA TDL, 
respectively, after nonspecific absorption with PVG RBC. xT, V: NRS binding to TDL and RBC, 
respectively. 
as well as the K/D-like locus(i) of H-1  a origin. Exhaustive absorption of the anti-H-1  a, 
anti-H-1A ~,  and  anti-H-1/V sera with  leukocyte-depleted preparations of RBC  was 
performed to determine whether detectable quantities of anti-Ia-like antibodies were 
present in the anti-H-1A ~ serum. The three antisera were diluted (anti-H~l  ~ and anti- 
H-1A=  to  1/100,  and  anti-H-IB= to  1/50)  and  300-#1  samples were  absorbed with 
serial fourfold doses of DA RBC, DA spleen cells, or PVG RBC  (for cell preparation 
and absorption methods see Materials and Methods). The absorbed sera were assayed 
for binding to DA RBC and DA TDL, using unabsorbed serum and NRS as positive 
and negative controls, respectively. 
DA spleen  cell absorptions  reduced  the  binding  activity on  DA  RBC  and TDL 
targets to the NRS level in all cases, while absorptions with PVG RBC had no effect 
at  all on the binding of the three sera. The effect of absorption with DA RBC was 
different in each of the three cases: 
(a)  absorption of the anti-H-I  a serum (1/100)  with DA RBC successfully removed 
binding  activity for DA RBC  targets,  but  only reduced  binding on DA TDL to a 
plateau which  was well above the NRS control  (Fig.  3).  Hence substantial  binding 
activity directed  at  non-RBC  antigens  was present  in  this  serum.  The unabsorbed 
and the DA RBC-absorbed anti-H-l= sera were also analyzed in the FACS for binding 
to  TDL  using  the  second  stage  fluoresceinated  anti-rat  Fc  reagent.  Whereas  the 
unabsorbed serum produced bright labeling of 98.7% of TDL, the DA RBC-absorbed 
serum did so for only 33.9%, and simultaneous labeling with anti-rat F(ab')2 demon- 
strated that these were the surface Ig-positive cells (33.4% labeled with both reagents 
together). This analysis of the anti-H-1  ~ serum showed that antibodies against Ia-like 
antigens could readily be detected in a complex antiserum by this method. GALLICO,  BUTCHER,  AND  HOWARD  249 
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FIG.  4.  Exhaustive absorption of the anti-H-l/~ serum with DA RBC does not reduce the level of 
binding to DA TDL. Absorption with DA spleen cells (&) reduces the binding to DA TDL to the 
NRS base line  (ll).  The specific DA  RBC  (0)  and the nonspecific PVG  RBC  (A)  absorptions 
remove no binding activity. 
(b)  Absorption of the anti-H-1/P serum (1/50) with >10 x° DA RBC/300 #1 had no 
effect on its binding to DA TDL (Fig. 4). FACS analysis showed that both before and 
after absorption of this antiserum with DA RBC,  33.5% of a  TDL population were 
labeled, and these were shown to be the Ig-positive cells. This demonstrated that the 
contamination  of the  DA RBC  preparation  with cells bearing Ia-like antigens  was 
very low and unlikely to affect the analysis of the anti-H-1A  a serum within fairly wide 
limits. 
(c)  Absorption of the anti-H-1A  a serum (1/100)  with DA RBC reduced binding to 
both DA RBC and TDL to the same level as the NRS control (Fig. 5): there was no 
plateau  of  residual  binding  to  TDL.  Similarly,  FACS  analysis  of  the  DA  RBC 
absorbed  anti-H-IA  a  serum with  a  fluoresceinated  anti-rat  Fc second stage reagent 
showed  no  cell-labeling  greater  than  NRS,  while  all  cells  were  labeled  by  the 
unabsorbed  antiserum.  Binding  activity against  Ia-like antigens  was  therefore  not 
detectable in the anti-H-1A  ~ serum. 
This analysis of the anti-H-lA  ~ serum suggested that antibodies against K/D-like 
antigens of the rat were indeed able to enhance renal allografts. It was clear, however, 
that better evidence in this matter would have to come from different approaches to 
the  problem;  special  arguments  involving  very  small  amounts  of  highly  potent 
enhancing antibodies, or enhancing antibodies restricted to Ig class(es) not detected 
by the second stage binding reagent, could not be discounted by these experiments. 
Monoclonal  antibodies  against  H-1A ~  region  K/D-like  determinants,  which  had 
recently been produced  (17,  18)  provided a  much more stringent  test of whether or 
not enhancement of renal allografts could be achieved through determinants of K/D- 
like antigens. 
One  such  monoclonal  antibody,  R3/13,  derived  from  an  AO  (H-1 w)  anti-DA 
immunization  (17,  18)  was used.  R3/13 culture supernate was salt precipitated and 250  MAJOR  HISTOCOMPATIBILITY COMPLEX REGIONS 
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FIG. 5.  Exhaustive absorption of the anti-H-/A =  serum with DA RBC reduces the level of binding 
to DA, RBC, and TDL to the level of NRS binding. I, O: binding to DA TDL after absorption 
with DA RBC and spleen cells, respectively. A: binding to DA RBC after absorption with DA 
RBC. &, Fl: binding to DA RBC and DA TDL, respectively, after nonspecific absorption with PVG 
RBC. $7, V: NRS binding to TDL and RBC, respectively. 
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FIo. 6,  The enhancement of 2/3 H-f'/H-F kidneys in PVG recipients treated with 2 ml R3/13 
clone product (0; O; D) compared with the rejection of similar transplants by hosts treated with 
culture medium alone (&; A; ml). 
concentrated ninefold, and 2 ml was given at  the time of transplantation  to each of 
three  PVG recipients  of H-la/H-I  c kidneys.  As a  control, a  sample of virgin culture 
medium was treated in the same way and injected into three more such recipients.  In 
this  experiment  all  rats  received  immediate  contralateral  nephrectomy.  All control 
rats and one of the experimentals rejected their kidneys and died by day 6. The other 
two recipients of R3/13 antibody survived long term, however, one after initial BUN 
elevation  (Fig. 6). This trial demonstrated  that antibodies against  K/D-like antigens GALLICO, BUTCHER,  AND HOWARD  251 
could enhance rat renal allografts, and that enhancement could be achieved through 
a single K/D-like determinant. 
Discussion 
The experiments described in this paper have used a recombinant of the rat MHC 
for the genetic analysis of the rejection and passive enhancement of renal allografts. 
Only a full 14-1  a haplotype difference led to rejection: neither an H-IA a nor an H-IB a 
difference was  sufficient to cause rejection (comparing single haplotype disparities 
only). Thus it appeared that the cofnbination of both H-IA  and H-IB  region antigens 
was required for rejection. 
Transplants in the H-Ia/H-lC---*  H-I c combination were difficult to enhance and 
complete  success  was  not  achieved.  Nevertheless,  antisera  against  antigens  of the 
entire H-1 ~ haplotype or against  either of the two subregions,  H-IA  or H-IB,  were 
able to enhance such grafts. Furthermore a monoclonal antibody, R3/13, directed at 
an H-1A  a antigenic determinant, was also able to enhance in a  full 17-1  ~ difference. 
Rejection.  The requirement for both H-1A ~ and H-IB a disparities to induce rejec- 
tion in these experiments does not necessarily imply synergistic interaction between 
subsets of recipient lymphocytes responding to the two sets of antigens. There is no 
clear evidence whether an additive or an interactive effect is at work. If additive, it 
may  simply  reflect  a  need  for  multiple  incompatibilities  to  achieve  rejection,  a 
requirement clearly seen in the rejection of mouse kidney grafts where multiple H-2 
and  non-H-2 differences led  to  late  rejection, while  kidneys presenting  H-2K  end 
(including  I-A  and  I-B)  or  H-2D  end  (including  I-C)  differences  were  accepted 
indefinitely (1O). The consistent early elevation of BUN seen in recipients of H-1B  ~ 
incompatible grafts (Fig. 2) suggested that this region does indeed include a histocom- 
patibility  locus  for kidney,  but  that  the  response was just  too weak  to  reject  the 
allograft before other immune mechanisms benign to the graft came into play. Thus 
H-1B  (Ia-like)  antigens  probably play more than just  an  amplifying role in  renal 
allograft  rejection, although  the  nonspecific increase in  the strength of a  rejection 
episode caused by allogeneic MLR-stimulating determinants is not denied. Such an 
allogeneic effect has been clearly demonstrated for thyroid allografts by Sollinger and 
Bach (20). 
Enhancement.  While  the  enhancement  with  the  antisera  against  the  full  H-1 ~ 
haplotype and the H-IB ~ region came as no surprise, the success with the anti-H-IA ~ 
antiserum and  the monoclonal antibody R3/13 was  inconsistent with the reported 
failure to enhance (LEW ×  BN)F1 kidney grafts in LEW recipients with alloantibodies 
eluted from platelets  (21).  Enhancement through  K/D-like antigens disagrees with 
the hypotheses of Davies  (8) and Soulillou et al.  (6)  which leave no place for K/D- 
directed antibodies in passive enhancement, and with McKenzie and Henning (22) 
who  suggested  that  anti-K/D  sera  were  only  graft  destructive.  The  results  are 
consistent, however, with other demonstrations of the enhancing capacity of anti-K/ 
D sera: the findings of Staines et al. (23) for mouse skin (only very slight prolongations, 
in this case);  those of Davis  (24)  for mouse heart;  and those of Duc et al.  (25)  for 
mouse sarcoma (Sa 1) and lymphoma (EL 4) allografts. 
It  would  seem  that  the  results  obtained  in  this  study are  best  described in  the 
following way. Both the H-1A  and H-IB  regions contain histocompatibility loci for 
skin allografts (10;  Butcher, unpublished observations) which are here presumed to 252  MAJOR HISTOCOMPATIBILITY  COMPLEX REGIONS 
be  relevant  to  kidney  graft  rejection.  H-IA ~  and  H-1B  ~  antigens  are  insufficient, 
however,  when  presented  alone,  to  cause  rejection  of a  kidney.  When  presented 
together, however, the kidney is rejected. Treatment of the allograft recipient with 
alloantibodies specific for antigens of one of the subregions (A or B)  of H-1 produces 
a  hyporesponsiveness towards the histocompatibility antigen(s)  of that region alone 
(perhaps by opsonisation of antigen reactive cells as suggested by Hutchinson and 
Zola (26), leaving responsiveness to the other subregion (B or A)  unaffected. In the 
case of the H-I~/H-lC---~ H-f  combination used here, this leads to graft survival since, 
as demonstrated, a single A  a or B  ~ subregion incompatibility is insufficient to produce 
rejection. 
Such a description can be made more general: the vigor of a rejection episode will 
depend  on the strength  of the  response to each of the  histocompatibility antigens 
presented by the graft. In different strain combinations the strengths of the responses 
to H-IA and H-1B antigens will vary: MHC-linked immune response gene control of 
the rejection of H-1A  disparate skin grafts has recently been demonstrated (Butcher, 
unpublished observations)  and there is no reason to expect kidneys to differ in this 
respect. In some combinations the H-IA  and H-IB  disparity alone may be sufficient 
to provoke rejection. Such considerations may explain the disagreement between the 
results presented here and those of Catto et al. (21)  who failed to enhance (LEW  × 
BN)F1  (H-It~H-1 n)  kidneys in LEW (H-fl)  recipients with LEW anti BN antibodies 
eluted from BN platelets. If in this latter combination the H-1B  n  incompatibility is 
alone sufficient to cause rejection (unlike the H-1tV difference in the present paper) 
then a hyporesponsiveness to H-1A ~ antigens produced by injection of the antibodies 
eluted from platelets would be irrelevant to rejection through the H-1B region. This 
emphasizes  the  importance  of using  several  genetic  combinations  in  the  study  of 
alloimmune phenomena. 
Summary 
The laboratory recombinant haplotype H-1 at1 of the Norway rat has been used in 
studies of the rejection and passive enhancement of kidney allografts. While the full 
H-I ~ haplotype provoked acute rejection, neither of the isolated subregions,  H-1A ~ 
and H-1B  ~, did so. It was also found that alloantisera raised against either the H-1A a 
or  the  H-1B  ~  antigens  would  enhance  the  grafts.  It  is  suggested  that  both  MHC 
subregions contain a histocompatibility locus (i) for kidney (as they do for skin) and 
that  in  the  genetic combinations studied  only incompatibility for both provokes a 
response sufficient for rejection. In other combinations, however, single region incom- 
patibilities may be sufficient. 
We thank Dr. Don W. Mason for discussions, Dr. R. Neal Smith for his criticisms of an earlier 
version of the text, and jenny Williams for typing the manuscript. 
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